The Female Health Co (FHCO)

1.40
0.04 3.32
NASDAQ : Consumer Goods
Prev Close 1.35
Open 1.37
Day Low/High 1.36 / 1.45
52 Wk Low/High 0.72 / 1.50
Volume 109.10K
Avg Volume 78.20K
Exchange NASDAQ
Shares Outstanding 53.21M
Market Cap 67.04M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Veru Healthcare To Advance Proprietary Drug For The Treatment Of Hot Flashes In Men Receiving Prostate Cancer Hormonal Therapy Following FDA Meeting

VERU-944 to Advance to Phase 2 Clinical Trial; 505(b)(2) Drug Candidate Addresses $600 Million Market, Potentially the First Drug for This Indication

Veru Healthcare Presents Results From Phase 4 Clinical Study Of PREBOOST For Management Of Premature Ejaculation

Veru Healthcare (NASDAQ: FHCO) today announced positive results from a Phase 4 clinical study of its proprietary product PREBOOST (topical 4% benzocaine wipes) for the management of premature ejaculation (PE).

The Female Health Company / Veru Healthcare Announces Presentation Of PREBOOST® Clinical Data At American Urological Association 2017 Annual Meeting

Abstract Selected for Podium Presentation and Inclusion in 2017 AUA Press Conference

This Biotech Small-Cap Has Big Ambitions

This Biotech Small-Cap Has Big Ambitions

Female Health Co./Veru Healthcare's stock is down, but the company says it's not out.

The Female Health Company / Veru Healthcare Initiates Bioequivalence Clinical Trial Comparing Tamsulosin DRS With FLOMAX®

Stage 1 of Clinical Trial Designed to Select Formulation; NDA Filing Under the 505(b)(2) Regulatory Pathway Late 2017 / Early 2018 And Approval Expected by Mid to Late 2018

Female Health Company / Veru Healthcare Announces Advancement Of Male Infertility Drug Candidate Following FDA Advisory Committee Meeting

Female Health Company / Veru Healthcare Announces Advancement Of Male Infertility Drug Candidate Following FDA Advisory Committee Meeting

-MSS-722 to Advance into Phase 2 Study; Trial Expected to Commence in 2017-

The Female Health Company / Veru Healthcare Appoints New President Of Global Public Health Sector Division

The Female Health Company / Veru Healthcare Appoints New President Of Global Public Health Sector Division

Company Promotes Denise van Dijk to President of Global Public Health Sector Division

The Female Health Company/Veru Healthcare Invited To Present At FDA Advisory Committee Meeting On December 6, 2016

The Female Health Company/Veru Healthcare Invited To Present At FDA Advisory Committee Meeting On December 6, 2016

Company to Discuss Clinical Trial Design and Primary Clinical Endpoints for Phase 2 Study of Its Drug Candidate for Male Infertility

The Female Health Company Adjourns Special Meeting Of Shareholders To October 31, 2016

The Female Health Company Adjourns Special Meeting Of Shareholders To October 31, 2016

Remaining Proposals Close to Receiving the Required Super Majority Vote